The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular ...

SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

A Durham company secured federal approval for its bioengineered tissue, which could become a revolutionary treatment for ...

The U.S. Food and Drug Administration approved Symvess, the first acellular tissue engineered vessel indicated for use in ...

The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.

Humacyte, Inc. announced that the FDA has granted full approval for the company’s Symvess—acellular tissue enginee ...

As of Friday’s premarket trading session, Humacyte’s stock surged +33.52% to $4.62, reflecting investor optimism following this groundbreaking news. While the company’s stock has had a solid +21.83% ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod ...

Highlights,FDA approves SYMVESS for urgent arterial injury treatment.,Clinical trials show high patency and low complication ...

Bayer announces positive results from phase III QUASAR study of aflibercept 8 mg in patients with macular edema following retinal vein occlusion: Berlin Thursday, December 19, 202 ...

Unique cell-impermeable1 design extends life-saving treatment for dialysis patientsMerit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Humacyte ( (HUMA) ) has issued an update.